Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease symbols : TAK save search
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published: 2024-04-18 (Crawled : 23:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
entyvio fda disease active for therapy
Polpharma Biologics' investigational biosimilar shows PK/PD comparability to inflammatory bowel disease blockbuster Entyvio®
Published: 2024-02-21 (Crawled : 08:00) - prnewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.88%
H: 0.34%
C: 0.34%
entyvio disease biosimilar
Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published: 2023-09-13 (Crawled : 13:30) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.63%
H: 0.5%
C: 0.31%
entyvio fda disease active therapy
Global Gaucher's Disease Treatment Market Research Report 2023: Emerging Therapies, Clinical Trials, Treatments, Current Scenario Evaluation, Patient Profile
Published: 2023-05-10 (Crawled : 18:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.92%
H: 0.0%
C: 0.0%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -1.83%
H: 0.12%
C: -3.06%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.4%
H: 0.34%
C: 0.19%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.11%
H: 0.22%
C: -0.52%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.57%
H: 0.37%
C: -0.01%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: 0.0%
disease report treatment research global market
First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead
Published: 2023-04-04 (Crawled : 17:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.12%
H: 1.55%
C: 1.03%
ARWR | $22.33 -1.24% -1.25% 960K
|
Health Technology
|
| O: 0.67%
H: 0.08%
C: -2.22%
liver disease payment milestone study
The Worldwide Lysosomal Disease Treatment Industry is Expected to Reach $11 Billion by 2028
Published: 2023-01-13 (Crawled : 13:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.13%
H: 0.76%
C: 0.76%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 2.77%
H: 0.63%
C: 0.63%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.13%
H: 2.35%
C: 2.16%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.44%
H: 1.39%
C: 0.74%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.15%
H: 0.65%
C: 0.4%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.47%
H: 0.47%
C: 0.14%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.13%
H: 1.04%
C: 0.57%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.89%
H: 0.0%
C: 0.0%
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: -1.16%
H: 2.27%
C: 0.42%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.27%
H: 0.78%
C: 0.15%
treatment disease expected
Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2023-01-09 (Crawled : 13:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.13%
H: 0.38%
C: -0.19%
ARWR | $22.33 -1.24% -1.25% 960K
|
Health Technology
|
| O: -19.61%
H: 3.16%
C: 0.77%
liver disease topline results study
Gastrointestinal Drugs Market Research Report by Drug Category, Route of Administration, Disease Type, End User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published: 2022-12-23 (Crawled : 15:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -3.13%
H: 0.0%
C: -0.23%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.13%
H: 0.71%
C: 0.65%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.14%
H: 0.28%
C: -0.11%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: 0.0%
covid-19 drug research global disease report impact gastrointestinal market
Global Rare Disease Drugs Market Report 2022-2027: Increasing Focus on Research Activities and Development of Novel Therapeutic Drugs to Facilitate Future Growth
Published: 2022-12-15 (Crawled : 18:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.71%
H: 0.07%
C: -1.05%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.71%
H: 0.08%
C: -1.07%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.59%
H: 0.44%
C: -0.48%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
rare research global disease report growth market
European Commission (EC) Approves LIVTENCITYTM▼ (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistance) to One or More Prior Therapies
Published: 2022-11-11 (Crawled : 11:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.87%
H: 0.95%
C: 0.95%
cytomegalovirus treatment disease one infection
European Commission (EC) Approves LIVTENCITYTM▼ (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistan...
Published: 2022-11-11 (Crawled : 11:00) - biospace.com/
RLYB | News | $1.75 4.79% 4.57% 310K
|
|
| O: -25.22%
H: 14.77%
C: 11.58%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.87%
H: 0.95%
C: 0.95%
cytomegalovirus treatment disease infection
Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy
Published: 2022-10-20 (Crawled : 12:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.6%
H: 0.6%
C: 0.04%
pharma disease collaboration agreement therapy
Prometheus Laboratories Announces Partnership with Takeda to Launch CDPATH™, a Personalized Prognostic Tool Advancing Innovation for Crohn's Disease Patients
Published: 2022-09-14 (Crawled : 13:20) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.0%
H: 0.52%
C: 0.15%
partnership disease innovation
Takeda Launches CDPATH™, a Personalized Prognostic Tool, Advancing Innovation for Patients with Crohn's Disease
Published: 2022-09-14 (Crawled : 12:00) - prnewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.0%
H: 0.52%
C: 0.15%
disease innovation
Lysosomal Disease Treatment Market to Reach $14.1 Billion, Globally, by 2031 at 6.4% CAGR: Allied Market Research
Published: 2022-09-06 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.93%
H: 10.14%
C: 3.79%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.44%
H: 0.0%
C: -1.11%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 1.22%
H: 0.46%
C: -1.12%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.54%
H: 3.26%
C: 1.28%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.35%
H: 0.0%
C: 0.0%
FOLD F | $10.62 2.81% 2.73% 2.5M
|
Health Technology
|
| O: 0.0%
H: 0.17%
C: -2.36%
treatment research disease market
8 MM Ulcerative Colitis Market Forecasts, Epidemiology & Pipeline Analysis 2022-2027: Novel Emerging Drugs will Shift the Inflammatory Bowel Disease (IBD) Treatment Paradigm
Published: 2022-09-02 (Crawled : 18:00) - prnewswire.com
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: 1.43%
H: 0.0%
C: 0.0%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.15%
H: 0.29%
C: -1.02%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.24%
H: 0.13%
C: -2.23%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.21%
H: 0.86%
C: -0.99%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 2.55%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.32%
H: 0.04%
C: -2.83%
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
|
| O: 1.06%
H: 1.35%
C: -3.15%
treatment disease market ulcerative colitis
U.S. Gastroesophageal Reflux Disease Devices Market Report 2022-2027: Key Players AstraZeneca, Pfizer, Procter & Gamble & Others Driving 15.47% Growth
Published: 2022-07-29 (Crawled : 20:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
| Email alert
Add to watchlist
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
| Email alert
Add to watchlist
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
| Email alert
Add to watchlist
disease report growth market
Global Crohn's Disease Treatment Market to Surpass US$ 15.17 Billion by 2030 - Coherent Market Insights
Published: 2022-07-13 (Crawled : 19:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.46%
H: 0.09%
C: 0.09%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.35%
H: 0.4%
C: 0.27%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.7%
H: 0.21%
C: 0.07%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -1.04%
H: 0.62%
C: 0.55%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -1.53%
H: 3.22%
C: 2.94%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -1.19%
H: 0.66%
C: 0.5%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -2.18%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.84%
H: 0.73%
C: 0.23%
treatment disease market
Global Alzheimer's Disease Treatment Markets, Analysis & Forecasts, 2016-2021, 2021-2026F, 2031F: Focus on Cholinergic, Memantine, Combined Drug, AChE inhibitors, Immunoglobulins
Published: 2022-06-02 (Crawled : 10:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.31%
H: 0.0%
C: 0.0%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -3.16%
H: 0.36%
C: -0.07%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.73%
H: 0.12%
C: 0.1%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.9%
H: 0.0%
C: 0.0%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -1.0%
H: 0.0%
C: 0.0%
treatment disease alzheimer's alzheimer’s
Insights on the Liver Disease Treatment Global Market to 2027 - by Treatment Type, Disease Type, End-user and Region
Published: 2022-04-12 (Crawled : 21:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 1.76%
H: 0.35%
C: 0.35%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.15%
H: 0.0%
C: -4.71%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: -0.83%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 2.3%
H: 0.55%
C: 0.36%
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 0.37%
H: 2.99%
C: 2.61%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.2%
H: 1.83%
C: 1.83%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.12%
H: 0.44%
C: 0.17%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.24%
H: 0.45%
C: 0.39%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.26%
H: 0.33%
C: -1.5%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.24%
H: 0.53%
C: 0.18%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -1.38%
H: 0.0%
C: -3.67%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.7%
H: 1.91%
C: 1.63%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.77%
H: 0.0%
C: 0.0%
treatment liver disease market